The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
GnRH antagonists have an immediate onset of action leading to a fast and profound suppression of testosterone and are therefore especially valuable in the treatment of patients with prostate cancer, where fast control of disease is needed. The GnRH antagonist abarelix was withdrawn from the United States market in 2005 and is now only marketed in Germany for use in patients with symptomatic prostate cancer. Degarelix is a GnRH antagonist that is approved for use in patients with advanced hormone-sensitive prostate cancer throughout Europe and also in the United States.
The Indian Army has its origins in the years after the Indian Rebellion of 1857, often called the Indian Mutiny in British histories, when in 1858 the Crown took over direct rule of British India from the East India Company. Before 1858, the precursor units of the Indian Army were units controlled by the Company and were paid for by their profits. These operated alongside units of the British Army, funded by the British government in London. The three Presidency armies remained separate forces, each with its own Commander-in-Chief. Overall operational control was exercised by the Commander-in-Chief of the Bengal Army, who was formally the Commander-in-Chief of the East Indies. From 1861, most of the officer manpower was pooled in the three Presidential Staff Corps. After the Second Afghan War a Commission of Enquiry recommended the abolition of the presidency armies. The Ordnance, Supply and Transport, and Pay branches were by then unified. The Punjab Frontier Force was under the direct control of the Lieutenant-Governor of the Punjab during peacetime until 1886, when it came under the Commander-in-Chief, India. The Hyderabad Contingent and other local corps remained under direct governmental control. Standing higher formations—divisions and brigades—were abandoned in 1889. No divisional staffs were maintained in peacetime, and troops were dispersed throughout the sub-continent, with internal security as their main function. In 1891 the three staff corps were merged into one Indian Staff Corps.
Familial intrahepatic cholestasis (FIH) is a group of disorders that lead to intrahepatic cholestasis in children. Most often, FIH occurs during the first year of life, with an incidence rate of 1/50,000 to 1/100,000. There are three different versions of FIH, with each causing a different severity of jaundice. Typically, children exhibit recurrent jaundice episodes, which eventually become permanent. Diagnosis usually occurs by analyzing laboratory features, liver biopsy results, DNA/RNA sequences, and biliary lipid analysis. The definitive treatment for FIH is liver transplant which usually results in a high recovery rate. Each type of FIH is a result of a different mutation. The three genes thought to be involved include APT8B1, which encodes for the FIC1 protein. The ABCB11 gene encodes for the bile salt export pump (BSEP) protein, and the ABCB4 gene encodes for the multidrug resistance 3 (MDR3) protein. BSEP and MDR3 are respectively responsible for transporting bile salt and phospholipid, two major constituents of bile, across the apical membrane of hepatocytes.
=== Children === Although this so-called "hypersomnolence" (excessive sleepiness) may also occur in children, it is not at all typical of young children with sleep apnea. Toddlers and young children with severe OSA instead ordinarily behave as if "over-tired" or "hyperactive"; and usually appear to have behavioral problems like irritability and an attention deficit. Adults and children with very severe OSA also differ in typical bodily habitus. Adults are generally heavy, with particularly short and heavy necks. Young children, on the other hand, are generally not only thin but may have "failure to thrive", where growth is reduced. Poor growth occurs for two reasons: the work of breathing is intense enough that calories are burned at high rates even at rest, and the nose and throat are so obstructed that eating is both tasteless and physically uncomfortable. OSA in children, unlike adults, is often caused by obstructive tonsils and adenoids and may sometimes be cured with tonsillectomy and adenoidectomy. This problem can also be caused by excessive weight in children. In this case, the symptoms are similar to those adults experience, such as restlessness and exhaustion. If adenotonsillar hypertrophy remains the most common cause of OSA in children, obesity can also play a role in the pathophysiology of upper airway obstruction during sleep which can lead to OSA, making obese children more likely to develop the condition.
The executive branch of government is responsible for managing the defense of Colombia, with the President commander-in-chief of the armed forces. The Ministry of Defence exercises day-to-day control of the military and the Colombian National Police. Colombia has 455,461 active military personnel. In 2016, 3.4% of the country's GDP went towards military expenditure, placing it 24th in the world. Colombia's armed forces are the largest in Latin America, and it is the second largest spender on its military after Brazil. In 2018, Colombia signed the UN treaty on the Prohibition of Nuclear Weapons. The Colombian military is divided into three branches: the National Army of Colombia; the Colombian Aerospace Force; and the Colombian Navy. The National Police functions as a gendarmerie, operating independently from the military as the law enforcement agency for the entire country. Each of these operates with their own intelligence apparatus separate from the National Intelligence Directorate (DNI, in Spanish). The National Army is formed by divisions, brigades, special brigades, and special units, the Colombian Navy by the Naval Infantry, the Naval Force of the Caribbean, the Naval Force of the Pacific, the Naval Force of the South, the Naval Force of the East, Colombia Coast Guards, Naval Aviation, and the Specific Command of San Andres y Providencia and the Aerospace Force by 15 air units.
Sources: en.wikipedia.org
== External links == Along the ancient silk routes: Central Asian art from the West Berlin State Museums, an exhibition catalog from The Metropolitan Museum of Art (fully available online as PDF), which contains material from Kizil Caves The Oases of the Northern Tarim Basin Revealing the Beauty of the Kizil Caves "Sackler Gallery exhibition in 2002– Caves as Canvas: Hidden Images of Worship Along the Ancient Silk Road". Smithsonian Institution. Archived from the original on 2003-01-03. Retrieved 2012-08-11. Kizil Paintings in the Hermitage Museum Kizil Paintings in the Dahlem Museum Archived 2024-12-06 at the Wayback Machine
During the later stages of World War II, the entire Cold War, and to a lesser extent afterwards, uranium-235 has been used as the fissile explosive material to produce nuclear weapons. Initially, two major types of fission bombs were built: a relatively simple device that uses uranium-235 and a more complicated mechanism that uses plutonium-239 derived from uranium-238. Later, a much more complicated and far more powerful type of fission/fusion bomb (thermonuclear weapon) was built, that uses a plutonium-based device to cause a mixture of tritium and deuterium to undergo nuclear fusion. Such bombs are jacketed in a non-fissile (unenriched) uranium case, and they derive more than half their power from the fission of this material by fast neutrons from the nuclear fusion process.
=== Final tour and death in New York === Thomas left Laugharne on 9 October 1953 on the first leg of his fourth trip to America. He called on his mother, Florence, to say goodbye: "He always felt that he had to get out from this country because of his chest being so bad." Thomas had suffered from chest problems for most of his life, though they began in earnest soon after he moved in May 1949 to the Boat House at Laugharne—the "bronchial heronry", as he called it. Within weeks of moving in, he visited a local doctor, who prescribed medicine for both his chest and throat. While waiting in London before his flight, Thomas stayed with the comedian Harry Locke and worked on Under Milk Wood. Locke noted that Thomas was having trouble with his chest, "terrible" coughing fits that made him go purple in the face. He was also using an inhaler to help his breathing. There were reports, too, that Thomas was also having blackouts. His visit to the BBC producer Philip Burton, a few days before he left for New York, was interrupted by a blackout. On his last night in London, he had another in the company of his fellow poet Louis MacNeice. Thomas arrived in New York on 20 October 1953 to undertake further performances of Under Milk Wood, organised by John Brinnin, his American agent and Director of the Poetry Centre. Brinnin did not travel to New York but remained in Boston to write. He handed responsibility to his assistant, Liz Reitell. She met Thomas at Idlewild Airport and was shocked at his appearance.
Holyhead (; Welsh: Caergybi pronounced [kɑːɨrˈɡəbi] , 'Cybi's fort') is a historic port town, and is the largest town and a community in the county of the Isle of Anglesey, Wales. Holyhead is on Holy Island, bounded by the Irish Sea to the north, and is separated from Anglesey island by the narrow Cymyran Strait. It was originally connected to Anglesey via the Four Mile Bridge. In the mid-19th century, Lord Stanley, a local philanthropist, funded the building of a larger causeway, known locally as "the Cobb"; it now carries the A5 and the railway line. The A55 dual carriageway runs parallel to the Cobb on a modern causeway. The town houses the Port of Holyhead, a major Irish Sea port for connections towards Ireland. The population of the town proper as of the 2021 census was 12,084, an increase on the 2011 census.
Sources: en.wikipedia.org
Bard (1933–2024), American chemist known for development of the scanning electrochemical microscope, Wolf Prize in Chemistry Vincenzo Barone (born 1952), Italian chemist working in theoretical and computational chemistry Denise Barthomeuf (1934-2004), French chemist working on zeolites Neil Bartlett (1932–2008), English/Canadian/American chemist known for creating the first noble-gas compound Sir Derek Barton (1918–1998), 1969 Nobel Prize in Chemistry for “contributions to the development of the concept of conformation and its application in chemistry"
Phosphotungstic acid haematoxylin (PTAH) is a mix of haematoxylin with phosphotungstic acid, used in histology for staining. It stains some tissue in contrasting colors in a way similar to haematoxylin and eosin stain, as phosphotungstic acid binds to tissue proteins. It is used to show gliosis in the central nervous system, tumours of skeletal muscles, and fibrin deposits in lesions. Muscle is stained blue-black to dark brown, connective tissue is pale orange-pink to brownish red, fibrin and neuroglia stain deep blue, coarse elastic fibers show as purple, and bone and cartilage obtain yellowish to brownish red color. PTAH is ideal for demonstrating striated muscle fibers and mitochondria, often without a counterstain. As such, it is used to identify contraction bands, as seen in contraction band necrosis. PTAH can be helpful in diagnosing oncocytomas, infantile digital fibromas. PTAH stains ependymomas while it does not stain choroid plexus papillomas, providing one means of differentiating these tumors. This technique has been largely replaced by immunohistochemistry techniques.
== mRNA == Messenger RNA (mRNA) is a single-stranded RNA molecule that is complementary to one of the DNA strands of a gene. An mRNA molecule transfers a portion of the DNA code to other parts of the cell for making proteins. DNA therapeutics needs access to the nucleus to be transcribed into RNA, and its functionality depends on nuclear envelope breakdown during cell division. However, mRNA therapeutics do not need to enter into the nucleus to be functional since it will be translated immediately once it has reached to the cytoplasm. Moreover, unlike plasmids and viral vectors, mRNAs do not integrate into the genome and therefore do not have the risk of insertional mutagenesis, making them suitable for use in cancer vaccines, tumor immunotherapy and infectious disease prevention.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.